

**Pharmacy and Therapeutics Committee
Meeting of December 7, 2004
Kellogg Center, Michigan State University
6PM**

Meeting Minutes

Welcome and Introductions:

The meeting was called to order at 6:05PM by Richard Slaughter, Chair. In attendance were Robert Coffey, PharmD., Rob Ernst, MD, Richard Slaughter, MSc., J. Fiechtner, MD, M. Robins, DO, J. Henry, MD, D. Eggleston, MD, and G. Perri, MD from the Committee. D. VanLoo, PharmD., had an excused absence. Also attending were, A. Paul, RPH., L. Jackson, PharmD., J. Coleman, Medicaid Policy, M. Sandusky, RPh., S. Moran, RN, G. Baker, MD, D. Quillan, Pharmacy Analyst

Public Comment:

J. Buonpastore, Xanodyne Pharmaceuticals, Hycet® *
S. Sherrod, MD, Xalatan® for open angle glaucoma *
L. Olson, Odyssey Pharmaceuticals, Sanctura® *
G. Honigfeld, Alamo Pharmaceuticals, Fazaclor® *
C. Hyde, Dr. B. Mathews, Aventis, Ketek® *
R. Detloff, Pfizer, G. Kuldaneck, M.D., Caduet® *
E. Crosby, Boehringer-Ingelheim, F. Martinez, MD., Spiriva®
G. Richardson, MD, Henry Ford Hospital, Sonata®
D. Sutton, MD, Concerta®
R. Mack, Sepracor, G. Zurkota, MD., Xopenex *
P. Miner, Novartis, Lotrel® *
M. Stevens, MD, R. Small, GlaxoSmithKline, Avandamet® *
A. Masterson, MD, Cymbalta® *

* denotes hand out materials supplied to the Committee

Review and Approval of Minutes of September Meeting

The minutes of the September 14, 2004 meeting were approved.

New Drug Reviews

Spiriva® The Committee voted to recommend this drug be added to the Michigan Pharmaceutical Products List(MPPL)

Cymbalta® The Committee voted to recommend this drug be added to the MPPL

Ertaczo® The Committee voted to recommend this drug be added to the MPPL

Ketek® The Committee recommended this drug be added with prior authorization requirements to be specified by the Anti-Infectives Workgroup, as a new class-Ketolides- to the Preferred Drug List (PDL)

Continued Discussion of ADHD drugs

Dr. Henry reported back to the Committee on his review of Concerta® and its relationship to other extended release methylphenidate products. Concerta® does not require prior authorization, and no changes were made to this PDL class

Age Edit for COX II Inhibitors

Dr. Fiechtner reported to the Committee on review of the medical literature as it pertains to the age at which the complications from non-steroidal anti-inflammatory drugs are felt to cause a higher rate of complications. Following discussion, the Committee recommended keeping the age where prior authorization is not required for Celebrx® and Bextra® to 60+

Committee Procedures and Establishment of Workgroups

Dr. Slaughter discussed with the Committee his plan to establish standing workgroups for the drug classes in the PDL, and to review those drugs on a standing schedule, rather than all at one time yearly. He explained his ideas of the purpose and conduct of the workgroups, and discussion followed, with the Committee voting to change its procedures to incorporate these changes. The Workgroups and schedule will be published on the web site www.Michigan.fhsc.com

The proposal is as follows:

PDL Working Groups

PDL Class	Primary Reviewer	Secondary Reviewer	Secondary Reviewer	First Health	Oregon Class Review (report dates)	P&T Meeting D
Analgesics	Fiechtner	Perri	Robbins	Paul	NSAIDS (3/05) Opioids, long acting (5/05)	December
Antibiotics/Anti-infectives	Van Loo	Perri	Robbins	Paul		June
Asthma/Allergy	Robbins	Van Loo	Slaughter	Paul	Antihistamines (11/05)	June
Cardiac 1	Ernst	Slaughter	Eggleston	Paul	ACEI (7/05) ARA (9/04,9/05) CCB (5/05)	February
Cardiac 2 (includes Caduet)	Coffey	Slaughter	Fiechtner	Paul	Statins (6/05) BB(5/05)	April
CNS	Henry	Perri	Eggleston	Paul	Alzheimers (4/05) ADHD (6/05)	December
Diabetes	Slaughter	Ernst	Coffey	Paul	Oral hypoglycemics (6/05)	September
Gastrointestinal	Eggleston	Perri	Van Loo	Paul	PPIs (5/05)	September

Miscellaneous	Perri	Fiechtner	Henry	Paul	Triptans (11/05) Urinary incontinence (2/05)	April
Therapeutic Controversies	Coffey	Slaughter	Ernst	Paul		February

2005 Meeting Schedule

Meeting	Key Questions Review	PDL Class Review
December 2004	Cardiac 1 Therapeutic Controversies	None
February 1, 2005	Cardiac 2 Miscellaneous	Cardiac 1 - Ernst Therapeutic Controversies - Coffey
April 5, 2005	Antibiotics/antiinfectives Asthma/allergy	Cardiac 2 - Coffey Miscellaneous - Perri
June 7, 2005	Diabetes Gastrointestinal	Antibiotics/antiinfectives – Van Loo Asthma/allergy - Robbins
September 13, 2005	Analgesics CNS	Diabetes - Slaughter Gastrointestinal - Eggleston
December 6, 2005	Cardiac 1 Therapeutic Controversies	Analgesics - Fiechtner CNS - Heny

Working Groups Key Questions for February 1, 2005 meeting

Cardiac 1 Drugs - Ernst

1. For adult patients with essential hypertension, heart failure, high cardiovascular riskfactors, diabetic nephropathy, nondiabetic nephropathy, or recent myocardial infarction, do angiotensin converting enzyme (ACE) inhibitors differ in effectiveness?
2. For adult patients with essential hypertension, heart failure, high cardiovascular risk factors, diabetic nephropathy, nondiabetic nephropathy, or recent myocardial infarction, do ACE inhibitors differ in safety or adverse events?
3. Are there subgroups of patients based on demographics (age, racial groups, gender), other medications, or co-morbidities for which one ACE inhibitor is more effective or associated with fewer adverse events?

Therapeutic Controversies – Fixed Dose Combination products - Coffey

What is the definition of a combination product? Can they be categorized?

What is the evidence that supports higher adherence rates in patients receiving combination products?

Are there certain patient groups that might benefit from the use of a combination product?

Are there circumstances when patients should be initiated on therapy with a combination product? Examples might be bactrim, augmentin, dyazide

Are there circumstances when it is more appropriate to initiate therapy with an individual agent? An example might be amlodipine and atorvastatin (caduet), or combination antihypertensives and hctz products.

Schedule for P and T Meetings, 2005

The Committee agreed on the following dates for meeting in Calendar Year 2005:

Tuesday, February 1, 2004

Tuesday, April 5, 2004

Tuesday, June 7, 2004

Tuesday, September 13, 2004

Tuesday, December 6, 2004

The Department will secure meeting location(s) and post. The meetings are scheduled to begin at 6 PM.